Corcept Therapeutics Inc
CORTHealthcare|Biotechnology|USA
$91.88
-1.37 (-1.47%)
DCF (FCF)
$25.10
Tangible Book
$5.94
Graham Number
$6.84
Earnings Power
$19.15
Upcoming Data Readouts (4)
Oct 2026
Est. completion
P1Nonalcoholic Steatohepatitis (NASH)
Evaluating the Pharmacokinetics and Safety of Miricorilant
NCT07553663n=15
Dec 2026
Est. completion
P2Cushing Syndrome
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
NCT03604198n=125
Sep 2027
Est. completion
P2Adenocarcinoma
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07259317n=80
Oct 2027
Est. completion
P2Metastatic Breast Cancer
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
NCT06099769n=201
Awaiting Results (2)
Trials past primary completion date but still active — data readout may be imminent.
Sep 2026
P2
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
NCT06108219Mar 2025
P3
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
NCT05257408